|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Stable transfection of IL-6-cDNA into HepG2 cells (HepG2-IL-6) resulting in constitutive secretion of 2 micrograms of IL-6 per 10(6) cells in 24 h led to a down-regulation of surface-bound gp80 and subsequent homologous desensitization of HepG2-IL-6 cells towards IL-6.
|
1321738 |
1992 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Twenty-seven IL-6 variants were tested for biological activity on a human hepatoma and a mouse hybridoma cell line.
|
1321818 |
1992 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The structure-function relationships of the biological activities of mutant varieties of the pleiotropic cytokine interleukin-6 (human) were measured by three assays: induction of immunoglobulin M (IgM) secretion from an Epstein-Barr virus-transformed human B cell line and induction of fibrinogen secretion from either a human hepatoma cell line or a rat hepatoma cell line.
|
1328443 |
1992 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
(b) Among peptides covering the entire sequence of human IL-6 and the corresponding antipeptide antibodies, the peptide IL-6[35-66] and anti-IL-6[35-66] most effectively inhibited the interaction between human hepatoma HepG2 cells and the preS(21-47) ligand, suggesting that this region of the human IL-6 sequence encompasses a binding site for the HBV env protein.
|
1334115 |
1992 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The regulation of the synthesis by the cytokines interleukin-1 (IL-1) and IL-6 of the positive acute-phase protein alpha 1-acid glycoprotein (AGP) and of the negative acute-phase protein alpha 2-HS glycoprotein (AHSG) has been studied in a long-term culture system of the human hepatoma cell line Hep3B.
|
1384466 |
1992 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this report, we demonstrate that human group II PLA2 expression and secretion are induced in hepatoma cells (HepG2) following treatment with interleukin-6 (IL-6), tumor necrosis factor (TNF), and interleukin-1 (IL-1).
|
1846631 |
1991 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the hepatoma line PLC/PRF/5, which contains 2,300 IL6 receptors, was more sensitive to IL6-PE40 (amount of protein required to inhibit protein synthesis by 50% was 5 ng/ml) than both the myeloma cell lines U266 and H929 (for both cell lines, the 50% inhibitory dose was 8 ng/ml), which contain 15,500 and 16,500 IL6 receptors, respectively.
|
2160579 |
1990 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Affinity cross-linking of 125I-labeled recombinant human interleukin-6 (IL-6) to human hepatoma cells (HepG2) allowed the detection of three IL-6-containing complexes with molecular masses of 100 kDa, 120 kDa and 200 kDa.
|
2163835 |
1990 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The transcription rate of the haptoglobin (Hp) gene is stimulated by interleukin-1 (IL-1), IL-6, and dexamethasone in rat hepatoma (H-35) cells.
|
2172789 |
1990 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The genomic Hp gene sequence spanning from -6500 to +6500, when transiently introduced into human hepatoma (HepG2) cells, directed IL-6- and dexamethasone-stimulated expression of rat Hp mRNA and protein.
|
2320005 |
1990 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we have treated the human hepatoma cell line Hep 3B with either crude MoCM or recombinant IL-6 and compared the effect of the two stimulants on the expression of both endogenous AP genes and recombinant plasmids introduced into the cells by transfection.
|
2457587 |
1988 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The qualitative response of HepG2 cells to HSF-III is essentially the same as that elicited by human recombinant interleukin-6 (IL-6).
|
2470740 |
1989 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A biological consequence of enhanced secretion of IFN-beta 2/IL-6 was the ability of media from infected FS-4 cell cultures to enhance by 8-15-fold the synthesis and secretion of a typical acute phase plasma protein (alpha 1-antichymotrypsin) by human hepatoma Hep3B2 cells.
|
3133443 |
1988 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Interleukin-6 (IL-6) causes the rapid activation of the acute-phase response factor (APRF) in the liver of animals during acute inflammation and in cultured human hepatoma cells (HepG2) and induces the transcription of the acute-phase protein genes, e.g. alpha 2-macroglobulin (alpha 2-M).
|
7519723 |
1994 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We and others have previously shown that the responsiveness to IL-6 is different in hepatoma and human primary hepatocytes.
|
7545121 |
1995 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutagenesis of a region of human interleukin (IL)-6 which is important for triggering signal transduction via the IL-6 receptor beta-chain (gp130) has lead to the isolation of a variant of human IL-6 (IL-6.Q160E/T163P), which could antagonize the biological activity of wild type IL-6 on the human EBV transformed B cell line CESS and the human hepatoma cell line HepG2.
|
7578977 |
1995 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among these, IL-6DBP/NF-IL6 plays a key role in IL-6 signal transduction because its trans-activation potential is induced by IL-6 in the human hepatoma cell line Hep3B.
|
7680115 |
1993 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We previously succeeded in developing receptor antagonists of IL-6 that antagonized wild-type IL-6 activity on the human Epstein-Barr virus (EBV)-transformed B cell line CESS and the human hepatoma cell line HepG2.
|
7964514 |
1994 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have analyzed the regulation of PAI-1 mRNA accumulation by interleukin (IL)-1, IL-6, and dexamethasone, known mediators of the acute phase response, in HepG2 cells, a highly differentiated human hepatoma cell line that produces a broad spectrum of acute phase proteins including PAI-1.
|
8034668 |
1994 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 production by human hepatoma lines is related to a low degree of cell differentiation.
|
8210716 |
1993 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To study the mechanism of interleukin-6 (IL-6) induction of human C-reactive protein (CRP) gene expression, we have utilized a human hepatoma (PLC/PRF/5) cell culture system to analyze the trans-acting factors which bind to the 300 bp 5'-flanking region of human CRP gene.
|
8703909 |
1996 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purified protein is biologically active, as determined by the ability to convert human hepatoma cells (HepG2) from nonresponsive to responsive to rat IL-6 and induce acute-phase protein synthesis.
|
8938575 |
1996 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We report here that interleukin-6 (IL-6), the principal cytokine mediating the synthesis of most acute-phase proteins in the liver, downregulates the production of factor XII by the human hepatoma cell line HepG2 by up to 75%.
|
9269767 |
1997 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We determined serum levels of IL-6 in patients with chronic hepatitis B (CH-B), chronic hepatitis C (CH-C), liver cirrhosis (LC) caused by hepatitis B, and LC with hepatocellular carcinoma (HCC) caused by hepatitis B (LC+HCC).
|
9676846 |
1998 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study on a human hepatoma cell line and primary rat hepatocytes examined how the effectiveness of IL-6 is modified by the presence of soluble IL-6 receptor and whether the sIL-6R in the absence of IL-6 acts on hepatocytes.
|
9722935 |
1998 |